AbbVie Inc. (ABBV) vs Roche Holding AG (RO.SW)

See how AbbVie Inc. and Roche Holding AG differ across market data and performance, so you can decide which asset best fits your strategy.

$265.72
NYSE
AbbVie Inc. is a pharmaceutical company with significant exposure to immunology through Humira, Skyrizi, and Rinvoq, and to oncology through Imbruvica and Venclexta. The company was spun off from Abbott in early 2013. Its 2020 acquisition of Allergan expanded its portfolio with additional products in aesthetics, including Botox. In 2024, AbbVie further strengthened its business through the acquisitions of Cerevel in neuroscience and ImmunoGen in oncology.
View Full Page
$454.43
Swiss
Roche Holding AG is a publicly traded company. It is a Swiss healthcare company focused on pharmaceuticals and diagnostics, including oncology, immunology, neuroscience, infectious disease, and laboratory testing. The company's performance is influenced by revenue growth, margins, capital allocation, competitive positioning, regulation, currency movements where relevant, and broader economic and market conditions affecting its industry.
View Full Page

Key Metrics Comparison

AbbVie Inc.ABBV
Market Cap
$469.463B
Price
$265.72
24h Change
+3.43%
24h Volume
$1.55M
Employees
57,000
Shares Outstanding
1,768,169,012
Roche Holding AGRO.SW
Market Cap
$362.073B
Price
$454.43
24h Change
+1.92%
24h Volume
$13.1K
Employees
N/A
Shares Outstanding
N/A

Category Performance

Visual comparison across key categories. Ring fill represents relative strength or share between the two assets.

Market Share

Share of combined market cap

Market Share
ABBV
56.5%
RO.SW
43.5%

Volume Share

Share of combined 24h volume

Volume Share
ABBV
99.2%
RO.SW
1.0%

24h Performance

Price change over last 24 hours

24h Performance
ABBV
3.43%
RO.SW
1.92%
Price Comparison
AbbVie Inc.
Roche Holding AG